Price Change to Note: What Next for Dimension Therapeutics Inc Stock After Touching Yearly Low?

Price Change to Note: What Next for Dimension Therapeutics Inc Stock After Touching Yearly Low?

The stock of Dimension Therapeutics Inc (NASDAQ:DMTX) hit a new 52-week low and has $3.87 target or 11.00% below today’s $4.35 share price. The 6 months bearish chart indicates high risk for the $98.23 million company. The 1-year low was reported on Nov, 9 by Barchart.com. If the $3.87 price target is reached, the company will be worth $10.81 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 272,106 shares traded hands or 296.37% up from the average. Dimension Therapeutics Inc (NASDAQ:DMTX) has declined 40.97% since April 7, 2016 and is downtrending. It has underperformed by 45.75% the S&P500.

Analysts await Dimension Therapeutics Inc (NASDAQ:DMTX) to report earnings on December, 2. They expect $-0.50 EPS, up 81.68% or $2.23 from last year’s $-2.73 per share. After $-0.49 actual EPS reported by Dimension Therapeutics Inc for the previous quarter, Wall Street now forecasts 2.04% negative EPS growth.

Dimension Therapeutics Inc (NASDAQ:DMTX) Ratings Coverage

Out of 5 analysts covering Dimension Therapeutics (NASDAQ:DMTX), 5 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Dimension Therapeutics has been the topic of 9 analyst reports since November 6, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating given on Monday, November 16 by Citigroup. Cantor Fitzgerald initiated the shares of DMTX in a report on Thursday, February 18 with “Buy” rating. Canaccord Genuity initiated the stock with “Buy” rating in Monday, November 16 report. The stock of Dimension Therapeutics Inc (NASDAQ:DMTX) has “Buy” rating given on Friday, June 3 by Cantor Fitzgerald. Goldman Sachs initiated the shares of DMTX in a report on Monday, November 16 with “Buy” rating. The firm has “Outperform” rating by Wells Fargo given on Friday, December 4. The rating was initiated by Goldman Sachs on Friday, December 4 with “Buy”. The rating was initiated by Roth Capital with “Buy” on Friday, November 6.

According to Zacks Investment Research, “Dimension Therapeutics, Inc. is a biotechnology company which focuses on developing novel, liver-directed gene therapy treatments for severe, rare genetic disorders. The company’s pipeline of programs includes DTX101, a lead gene therapy product candidate designed to deliver Factor IX, gene expression for hemophilia B; DTX301, a gene therapy product candidate for the treatment of patients with ornithine transcarbamylase deficiency; DTX401, a gene therapy program for the treatment of patients with glycogen storage disease type Ia, a disease that arises from a defect in glucose-6-phosphatase and DTX201, a gene therapy program for the treatment of hemophilia A, which are in different clinical trial stage. Dimension Therapeutics, Inc. is based in Cambridge, Massachusetts.”

More recent Dimension Therapeutics Inc (NASDAQ:DMTX) news were published by: Marketwatch.com which released: “Dimension Therapeutics Inc.” on July 22, 2014. Also Quotes.Wsj.com published the news titled: “News Dimension Therapeutics Inc.DMTX” on September 23, 2015. Globenewswire.com‘s news article titled: “Dimension Therapeutics Announces Preclinical Data from Bayer-Partnered …” with publication date: May 07, 2016 was also an interesting one.

DMTX Company Profile

Dimension Therapeutics, Inc., incorporated on June 20, 2013, is a gene therapy company. The Firm is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. The Firm has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa). The Company’s gene therapy product candidates and programs are designed to provide a functional copy of an abnormal or missing gene using the advanced adeno-associated virus (AAV) vector delivery technology. The Firm uses mammalian cells in its manufacturing approach for its AAV product candidates. The Company’s AAV manufacturing is performed in over two mammalian cell types, human embryonic kidney 293 cells (HEK293 cells) and HeLa cells.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment